BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22246202)

  • 1. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.
    Venkataraman S; Alimova I; Tello T; Harris PS; Knipstein JA; Donson AM; Foreman NK; Liu AK; Vibhakar R
    J Neurooncol; 2012 May; 107(3):517-26. PubMed ID: 22246202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
    Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
    Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
    Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
    Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases expression in atypical teratoid rhabdoid tumors.
    Sredni ST; Halpern AL; Hamm CA; Bonaldo Mde F; Tomita T
    Childs Nerv Syst; 2013 Jan; 29(1):5-9. PubMed ID: 23143003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
    Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
    Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
    Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
    Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
    Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
    Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
    Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
    Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
    Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
    Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
    Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
    Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
    Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
    Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
    Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.
    Torchia J; Golbourn B; Feng S; Ho KC; Sin-Chan P; Vasiljevic A; Norman JD; Guilhamon P; Garzia L; Agamez NR; Lu M; Chan TS; Picard D; de Antonellis P; Khuong-Quang DA; Planello AC; Zeller C; Barsyte-Lovejoy D; Lafay-Cousin L; Letourneau L; Bourgey M; Yu M; Gendoo DMA; Dzamba M; Barszczyk M; Medina T; Riemenschneider AN; Morrissy AS; Ra YS; Ramaswamy V; Remke M; Dunham CP; Yip S; Ng HK; Lu JQ; Mehta V; Albrecht S; Pimentel J; Chan JA; Somers GR; Faria CC; Roque L; Fouladi M; Hoffman LM; Moore AS; Wang Y; Choi SA; Hansford JR; Catchpoole D; Birks DK; Foreman NK; Strother D; Klekner A; Bognár L; Garami M; Hauser P; Hortobágyi T; Wilson B; Hukin J; Carret AS; Van Meter TE; Hwang EI; Gajjar A; Chiou SH; Nakamura H; Toledano H; Fried I; Fults D; Wataya T; Fryer C; Eisenstat DD; Scheinemann K; Fleming AJ; Johnston DL; Michaud J; Zelcer S; Hammond R; Afzal S; Ramsay DA; Sirachainan N; Hongeng S; Larbcharoensub N; Grundy RG; Lulla RR; Fangusaro JR; Druker H; Bartels U; Grant R; Malkin D; McGlade CJ; Nicolaides T; Tihan T; Phillips J; Majewski J; Montpetit A; Bourque G; Bader GD; Reddy AT; Gillespie GY; Warmuth-Metz M; Rutkowski S; Tabori U; Lupien M; Brudno M; Schüller U; Pietsch T; Judkins AR; Hawkins CE; Bouffet E; Kim SK; Dirks PB; Taylor MD; Erdreich-Epstein A; Arrowsmith CH; De Carvalho DD; Rutka JT; Jabado N; Huang A
    Cancer Cell; 2016 Dec; 30(6):891-908. PubMed ID: 27960086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
    Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
    Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
    Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.
    Giang LH; Wu KS; Lee WC; Chu SS; Do AD; Changou CA; Tran HM; Hsieh TH; Chen HH; Hsieh CL; Sung SY; Yu AL; Yen Y; Wong TT; Chang CC
    J Exp Clin Cancer Res; 2023 Dec; 42(1):346. PubMed ID: 38124207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.